Celcuity's cancer drug launch delayed pending FDA inspection of second manufacturing site

Celcuity explained that the slower-than-expected commercial launch of its approved cancer drug is due to awaiting FDA review of a second manufacturing facility. The company is working to resolve the regulatory hurdle to expedite product availability. The delay has affected investor expectations.